Literature DB >> 34169367

Radiomics analysis of [18F] FDG PET/CT for microvascular invasion and prognosis prediction in very-early and early-stage hepatocellular carcinoma.

Wenfei Li1, Tahir Mehmood Shakir2, Yuemei Zhao1, Zhanqiu Wang3.   

Abstract

Entities:  

Year:  2021        PMID： 34169367     DOI： 10.1007/s00259-021-05479-w

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  4 in total

1.  Harvest of at least 18 lymph nodes is associated with improved survival in patients with pN0 colon cancer: a retrospective cohort study.

Authors:  Fei-Long Ning; Jun-Peng Pei; Nan-Nan Zhang; Jun Wang; Hong-Guang Quan; Zu-Bing Mei; Xian-Tao Zeng; Masanobu Abe; Chun-Dong Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-13       Impact factor: 4.553

2.  Radiomic Features at Contrast-enhanced CT Predict Recurrence in Early Stage Hepatocellular Carcinoma: A Multi-Institutional Study.

Authors:  Gu-Wei Ji; Fei-Peng Zhu; Qing Xu; Ke Wang; Ming-Yu Wu; Wei-Wei Tang; Xiang-Cheng Li; Xue-Hao Wang
Journal:  Radiology       Date:  2020-01-14       Impact factor: 11.105

3.  Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.

Authors:  Yaqi Li; Lei Liang; Weixing Dai; Guoxiang Cai; Ye Xu; Xinxiang Li; Qingguo Li; Sanjun Cai
Journal:  Mol Cancer       Date:  2016-08-24       Impact factor: 27.401

4.  A radioiodinated FR-β-targeted tracer with improved pharmacokinetics through modification with an albumin binder for imaging of macrophages in AS and NAFL.

Authors:  Xuejun Wen; Changrong Shi; Liu Yang; Xinying Zeng; Xiaoru Lin; Jinxiong Huang; Yesen Li; Rongqiang Zhuang; Haibo Zhu; Zhide Guo; Xianzhong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-21       Impact factor: 9.236
  4 in total
  1 in total

1.  Prognostic Value of Radiomic Features of 18F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells.

Authors:  Yeye Zhou; Jihui Li; Xiaoyi Zhang; Tongtong Jia; Bin Zhang; Na Dai; Shibiao Sang; Shengming Deng
Journal:  Front Oncol       Date:  2022-02-07       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.